PDS Biotechnology Ownership
| PDSB Stock | USD 2.20 0.17 8.37% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 36.7 M | Current Value 36.8 M | Avarage Shares Outstanding 13.7 M | Quarterly Volatility 13.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
PDS |
PDS Stock Ownership Analysis
The book value of the company was at this time reported as 0.79. The company recorded a loss per share of 1.17. PDS Biotechnology Corp last dividend was issued on the 18th of March 2019. The entity had 1:20 split on the 18th of March 2019. PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. Pds Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To find out more about PDS Biotechnology Corp contact Frank BeduAddo at 800 208 3343 or learn more at https://www.pdsbiotech.com.Besides selling stocks to institutional investors, PDS Biotechnology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different PDS Biotechnology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align PDS Biotechnology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
PDS Biotechnology Quarterly Liabilities And Stockholders Equity |
|
PDS Biotechnology Insider Trades History
Roughly 4.0% of PDS Biotechnology Corp are currently held by insiders. Unlike PDS Biotechnology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against PDS Biotechnology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of PDS Biotechnology's insider trades
PDS Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PDS Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PDS Biotechnology Corp backward and forwards among themselves. PDS Biotechnology's institutional investor refers to the entity that pools money to purchase PDS Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jane Street Group Llc | 2024-06-30 | 114 K | Northern Trust Corp | 2024-09-30 | 92.8 K | Commonwealth Equity Services Inc | 2024-06-30 | 78.9 K | Amussen, Hunsaker & Associates Incorporated | 2024-06-30 | 75 K | Alpine Partners Vi, Llc | 2024-06-30 | 75 K | Ubs Group Ag | 2024-06-30 | 60 K | Cubist Systematic Strategies, Llc | 2024-06-30 | 49.8 K | Citadel Advisors Llc | 2024-06-30 | 48.7 K | Centiva Capital Lp | 2024-06-30 | 48 K | Vanguard Group Inc | 2024-09-30 | 1.5 M | Blackrock Inc | 2024-06-30 | 487 K |
PDS Biotechnology Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PDS Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on PDS Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PDS Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PDS Biotechnology Outstanding Bonds
PDS Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PDS Biotechnology Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PDS bonds can be classified according to their maturity, which is the date when PDS Biotechnology Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US70466WAA71 Corp BondUS70466WAA71 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US70462GAC24 Corp BondUS70462GAC24 | View | |
| US70462GAA67 Corp BondUS70462GAA67 | View | |
| US70462GAB41 Corp BondUS70462GAB41 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
PDS Biotechnology Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 29th of January 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.